Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYing Yang

Discussion

Loading...

Member takes

Overview

Investigator-initiated trials showed 100% response rate in NDMM patients using dual targeting CAR-T therapy, indicating strong potential for treatment.

Key Points

  • Evaluate safety and efficacy of GC012F/AZD0120 in patients with newly diagnosed multiple myeloma.
  • Conducted two open-label phase 1 trials (NCT04935580, NCT05840107).
  • Patients received GC012F/AZD0120 infusion following RVd induction therapy.
  • Assessed MRD negativity and overall response rates after treatment.
  • 100% overall response rate (ORR) and 97% stringent complete response (sCR) rate.
  • Median progression-free survival (PFS) was 88% at 30 months.
  • Cytokine release syndrome (CRS) occurred in 33% of patients, all grade 1-2.

Cite This Study

Ying Yang (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1e6https://doi.org/10.1182/blood-2025-258
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study2025 · 10 citations
  2. 2One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus2025 · 1 citations
  3. 3BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  4. 4ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)2025
  5. 5An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients2025